Navigating Policy and Utilization Management in Oncology: Aligning Evidence with Access
EP. 1: Impact of Recent Policies on US Health Care System and Oncology Practice
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how national policy reforms are reshaping oncology care by balancing affordability efforts with the need to preserve access and innovation.
EP. 2: Bridging Policy Change With Patient Access and Care Delivery in Oncology
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how aligning evolving payer policies with real-world oncology practice is key to sustaining timely and equitable patient access.
EP. 3: Role of Pharmacy Benefit Managers in Oncology
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how PBMs shape oncology access and stress the need for transparency to align financial control with clinical priorities.
EP. 4: Impact of Utilization Management Policies in Oncology
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how utilization management policies can delay oncology care and call for reforms that better align oversight with clinical evidence.
EP. 5: Challenges of Step Edits in Oncology
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how step edits hinder timely cancer treatment and urge policies that prioritize evidence-based access over cost-driven sequencing.
EP. 6: Understanding Gaps in Aligning Coverage Policy With Innovation in Oncology
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how outdated coverage models lag behind oncology innovation, calling for dynamic policies that reflect evolving clinical evidence.
EP. 7: Disconnect Between NCCN Guidelines and Coverage Decisions With BTK Inhibitors in CLL
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how payer coverage restrictions often conflict with NCCN guidelines for BTK inhibitor therapies in CLL, impeding evidence-based care.
EP. 8: Impact of Evidence-Coverage Misalignment on Patient Outcomes With BTK Inhibitors in CLL
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how outdated coverage decisions can worsen outcomes and increase costs by delaying access to safer, evidence-supported BTK inhibitor therapies.
EP. 9: Using Real-World Evidence of BTK Inhibitors to Inform Coverage Decisions in CLL
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how integrating real-world evidence into coverage frameworks can enhance decision-making and align payer policies with actual patient outcomes.
EP. 10: Balancing Black Box Warnings With Real-World Oncology Practice
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how payers should interpret black box warnings with clinical context to prevent unnecessary restrictions on safe, evidence-based treatments.
EP. 11: Impact of Utilization Management on Physician Autonomy and Shared Decision-Making in Oncology
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how utilization management limits clinical autonomy and advocate for reforms that preserve shared, patient-centered decision-making.
EP. 12: Shaping Oncology Policy Through Access and Safety Considerations
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how integrating safety and access considerations into oncology policy can create more equitable, patient-centered coverage models.
EP. 13: Impact of Inflation Reduction Act and the Drug Price Negotiation Program in Oncology
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how the IRA’s drug pricing reforms aim to improve affordability but may influence future oncology innovation.
EP. 14: Implications of IRA Drug Pricing Negotiations on BTK Inhibitors in CLL
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how IRA-driven BTK inhibitor price changes could shift payer preferences, necessitating vigilance to preserve clinical integrity in treatment selection.
EP. 15: The Future of Oncology Research in a Shifting Policy Landscape
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Olalekan Ajayi, PharmD, MBA, FACC,Taral Patel, MD,Nick Bouchard, PharmD Panelists discuss how evolving policy reforms will reshape oncology research by balancing innovation, access, and affordability.
